GYG2

Across TCGA pan-cancer cohorts, GYG2 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated GYG2 data layer compared with 26 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher GYG2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated GYG2 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

LUAD, LSCC, and PDAC are the cancer types where GYG2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.951	0.629	.004	22	view →
LSCC	DFS	Median	II,III,IV	0.652	0.890	.012	8	view →
PDAC	DFS	Tertile	II,III,IV	0.655	0.832	.024	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

GYG2–LUAD (OS)

Open the LUAD breakdown →